Misplaced Pages

Suritozole

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 11:33, 3 September 2011 (Updating {{drugbox}} (changes to watched fields - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|er). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 11:33, 3 September 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to watched fields - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|er)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Suritozole
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
CAS Number
PubChem CID
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H10FN3S
Molar mass223.269 g/mol g·mol
3D model (JSmol)
SMILES
  • Cn1c(=S)n(C)nc1-c2cccc(F)c2
  (verify)

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel compex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM. It was investigated for the treatment of depression and Alzheimer's disease, but clinical development seems to have been discontinued.

References

  1. Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM (1992). "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86. PMC 1907590. PMID 1330168. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ (1997). "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos. 18 (4): 325–34. doi:10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1. PMID 9158880. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Psychostimulants, agents used for ADHD, and nootropics (N06B)
N06BA
Centrally acting sympathomimetics
Amphetamine
Armodafinil
Atomoxetine
Dextroamphetamine
Dextromethamphetamine
Fencamfamin
Fenetylline
Fenozolone
Lisdexamfetamine
Methylphenidate (Dexmethylphenidate)
Modafinil
Pemoline
Serdexmethylphenidate
Solriamfetol
N06BC
Xanthine derivatives
Caffeine
Propentofylline
N06BX
Other psychostimulants and nootropics
Acetylcarnitine
Adrafinil
Aniracetam
Citicoline
Deanol
Fipexide
Idebenone
Linopirdine
Mebicar
Meclofenoxate
Nizofenone
Oxiracetam
Phenibut
Pipradrol
Piracetam
Pirisudanol
Pramiracetam
Prolintane
Pyritinol
Vinpocetine
Index of psychology and psychiatry
Description
Disorders
Treatment
GABA receptor modulators
Ionotropic
GABAATooltip γ-Aminobutyric acid A receptor
GABAA-ρTooltip γ-Aminobutyric acid A-rho receptor
Metabotropic
GABABTooltip γ-Aminobutyric acid B receptor
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Suritozole Add topic